Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer

This randomized phase III trial studies how well netupitant/palonosetron hydrochloride and dexamethasone with prochlorperazine or olanzapine work compared to netupitant/palonosetron hydrochloride and dexamethasone in improving chemotherapy-induced nausea and vomiting in patients with breast cancer. Antiemetic drugs, such as prochlorperazine and olanzapine, may help lessen nausea and vomiting in patients with breast cancer treated with chemotherapy.

Research Base: Gary Morrow
NCT ID: NCT03367572
NCI Protocol Number: URCC-16070
Status: Recruiting

For more information see ClinicalTrials.gov

Interventions

Dexamethasone; Laboratory Biomarker Analysis; Netupitant/Palonosetron Hydrochloride; Olanzapine; Placebo; Prochlorperazine; Quality-of-Life Assessment

Condition

Breast Carcinoma

Trial Type

Supportive Care/Symptom Management/PROs

See a list of participating sites on ClinicalTrials.gov


˄
BACK TO
TOP